As part of CLL Global Research Foundation’s virtual town hall, Dr. Alessandra Ferrajoli responded to an audience question, addressing how research funding has been impacted for CLL and why there is hope for the future.
Expert Panel:

Dr. Alessandra Ferrajoli, The University of Texas MD Anderson Cancer Center
Transcript:
Jeff Folloder: We all know there’s NIH, National Institution of Health, spending cuts. Those cuts are likely going to impact basic science research and progress. Do you think it’s going to impact CLL?
Is there reason for concern, or should we still be hopeful? Dr. Ferrajoli?
Dr. Alessandra Ferrajoli: So, I think we should be hopeful because the field is evolving so fast and so well. However, there is definitely reason for concern. The way to see it is that the research that is being impacted, as you said, is the very early research. It’s where there is not a financial incentive in conducting that research. That very early research then becomes more advanced research and close to drug development and even further, close to drug approval. The later drug development and drug approval are really mostly supported financially by the pharmaceutical industry or by organizations like CLL Global or ASCO or ASH.
But the early, the very important early research is supported by NIH. I have had many patients asking me this question in the clinic. My way of answering is we won’t feel it now, but we are likely going to see a slowdown in progress maybe five, seven years from now.